Necrobiosis Lipoidica Diabeticorum

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

CLINICAL_TRIALS trial_result · 2024-05-17
Clinical Trial Update: Secukinumab for NLD (Cosentyx) in Patients With Necrobiosis Lipoidica Diabeticorum (NLD) [Phase 2]
Phase 2 trial of secukinumab (Cosentyx) for Necrobiosis Lipoidica Diabeticorum was terminated. Results have been posted.